The INTRICATE program has brought forward a strategic platform biomedical nanotechnology to develop assets in the field of rheumatology, orthopedics and tissue engineering.
Using several building blocks, such as polypeptides and nanotech biopolymers, this unique platform can generate assets with selectable biological and mechanical properties.
These assets can achieve their disease-modifying effect through direct interactions at the cellular level, or indirectly as a tuneable vehicle for combination products.